Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
NAFLD Clinical Trials Market Report Overview
The NAFLD clinical trial market research report provides an overview of the NAFLD clinical trials scenario. The report provides top-line data relating to the clinical trials on NAFLD. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
NAFLD Clinical Trials Market Segmentation by Regions and Countries
The key regions in the NAFLD clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. Asia-Pacific dominates the market with more than 30% of clinical trials conducted, as of December 2022.
In the country-wise analysis, Iran has the highest number of non-alcoholic fatty liver disease clinical trials, as of December 2022. China has the highest average patient enrollment in non-alcoholic fatty liver disease clinical trials, as of December 2022.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of NAFLD in Gastrointestinal clinical trials as of December 2022.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of NAFLD in Gastrointestinal clinical trials as of December 2022.
NAFLD Clinical Trials Analysis by Regions
For more regional insights into the NAFLD clinical trials market, download a free report sample
NAFLD Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the NAFLD clinical trials market are institution, company, and the government. Out of them, the institution segment dominates the market.
NAFLD Clinical Trials Market Analysis by Sponsor Types
For more sponsor type insights into the NAFLD clinical trials market, download a free report sample
NAFLD Clinical Trials Market - Competitive Landscape
The leading sponsors in the NAFLD clinical trials market are Pfizer Inc, Galmed International Ltd, AstraZeneca Plc, Novartis AG, ICON Plc, ProSciento Inc, and Gilead Sciences Inc among others. Pfizer Inc has conducted the highest number of non-alcoholic fatty liver disease clinical trials.
NAFLD Clinical Trials Market Analysis by Sponsors
To know more about the leading players in the NAFLD clinical trials market, download a free report sample
NAFLD Clinical Trials Market Report Overview
Key Regions | North America, Asia-Pacific, Europe, Middle East & Africa, and South & Central America |
Key Countries | The US, Iran, China, Japan, the UK, India, and Canada |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Pfizer Inc, Galmed International Ltd, AstraZeneca Plc, Novartis AG, ICON Plc, ProSciento Inc, and Gilead Sciences Inc |
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) about the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies for investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Galmed International Ltd
AstraZeneca Plc
Novartis AG
ICON Plc
ProSciento Inc
Gilead Sciences Inc
Thermo Fisher Scientific Inc
Ascletis Pharma Inc
Novo Holdings AS
Table of Contents
Frequently asked questions
-
What are the key regions in the NAFLD clinical trials market?
The key regions in the NAFLD clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others.
-
What are the key countries in the NAFLD clinical trials market?
The key countries in the NAFLD clinical trials market are the US, Iran, China, Japan, the UK, India, and Canada.
-
What are the key sponsor types in the NAFLD clinical trials market?
The key sponsor types in the NAFLD clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the NAFLD clinical trials market?
The leading sponsors in the NAFLD clinical trials market are Pfizer Inc, Galmed International Ltd, AstraZeneca Plc, Novartis AG, ICON Plc, ProSciento Inc, and Gilead Sciences Inc
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Gastrointestinal reports

